ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Deparle Leaves HCFA; Speyer Promoted At NYU Center.

September 15, 2000

New Drug Reverses Damage To Liver In Stem Cell Transplant

September 27, 2002

NCI Director Klausner Resigns To Head Institute Begun By AOL Chairman Case.

September 14, 2001

Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside Of A Registry Trial

July 4, 2014

St. Jude Begins $100 Million Expansion Program

December 4, 1987

NCI, Dept. of Veteran’s Affairs Sign Agreement On Clinical Trials Access

November 1, 1996